ArticleJournal of biomedical optics2025
Epidermal growth factor receptor-targeted near-infrared probe cetuximab-IRDye800CW enables stable and tumor-specific fluorescence imaging in colorectal cancer models.
Article in Journal of biomedical optics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significance: Colorectal cancer (CRC) remains a major cause of cancer-related mortality, with incomplete resection contributing to recurrence and poor survival. Improving intraoperative margin detection is critical to enhance surgical precision and patient outcomes. Aim: We aim to evaluate the tumor-targeting specificity of cetuximab-IRDye800CW (Cet-IRDye800CW), an epidermal growth factor receptor (EGFR)-specific near-infrared probe, for fluorescence-guided surgery in CRC models. Approach: Cet-IRDye800CW and IgG-IRDye800CW controls were synthesized and tested in LS174T and SW948 xenografts as well as patient-derived xenografts (PDXs). Mice received Results: Cetuximab-IRDye800CW significantly enhanced tumor fluorescence compared with controls in all models ( Conclusion: Cetuximab-IRDye800CW provides stable, tumor-specific, high-contrast fluorescence imaging in EGFR-high CRC models. These findings validate its molecular targeting capability and support its translational potential for fluorescence-guided CRC surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.